- Home
- CNTB vs PSNL Comparison
CNTB vs PSNL Comparison
Compare CNTB & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- PSNL
- Stock Information
- Founded
- CNTB 2012
- PSNL 2011
- Country
- CNTB United States
- PSNL United States
- Employees
- CNTB N/A
- PSNL N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- CNTB Health Care
- PSNL Health Care
- Exchange
- CNTB Nasdaq
- PSNL Nasdaq
- Market Cap
- CNTB 68.5M
- PSNL 321.1M
- IPO Year
- CNTB 2021
- PSNL 2019
- Fundamental
- Price
- CNTB $1.17
- PSNL $5.19
- Analyst Decision
- CNTB Strong Buy
- PSNL Strong Buy
- Analyst Count
- CNTB 1
- PSNL 4
- Target Price
- CNTB $8.00
- PSNL $6.81
- AVG Volume (30 Days)
- CNTB 24.6K
- PSNL 439.4K
- Earning Date
- CNTB 09-05-2024
- PSNL 11-06-2024
- Dividend Yield
- CNTB N/A
- PSNL N/A
- EPS Growth
- CNTB N/A
- PSNL N/A
- EPS
- CNTB N/A
- PSNL N/A
- Revenue
- CNTB $24,116,000.00
- PSNL $80,027,000.00
- Revenue This Year
- CNTB N/A
- PSNL $10.85
- Revenue Next Year
- CNTB $63.90
- PSNL $8.77
- P/E Ratio
- CNTB N/A
- PSNL N/A
- Revenue Growth
- CNTB N/A
- PSNL 19.20
- 52 Week Low
- CNTB $0.68
- PSNL $0.89
- 52 Week High
- CNTB $2.84
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- PSNL 56.29
- Support Level
- CNTB $1.18
- PSNL $4.54
- Resistance Level
- CNTB $1.26
- PSNL $5.35
- Average True Range (ATR)
- CNTB 0.07
- PSNL 0.30
- MACD
- CNTB -0.01
- PSNL 0.05
- Stochastic Oscillator
- CNTB 13.59
- PSNL 84.71
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.